iHealthScreen Inc. Announces CE Certification for iPredict™ Automated AI System for Early Diagnosis of Diabetic Retinopathy , Age Related Macular Degeneration , and Glaucoma Suspect. Using the iPredict™ System, primary care and various specialty practices can accurately and efficiently screen diabetic patients for DR, people over 50 for AMD, and those with a family history of glaucoma or other risk factors for suspected glaucoma.
iPredict’s CE certification indications for use as follows:iPredict-DR can detect more than mild DR or vision threatening DR such as severe non-Proliferative DR, proliferative and diabetic macular EDEMA.iPredict-AMD can detect referable AMD such as intermediate to late AMD and non-referable AMD such as early or none.iPredict-glaucoma detects glaucoma suspects based on abnormal optic discs.
If referable stage disease is detected for any of these conditions, the iPredict automated report recommends a visit to an Ophthalmologist for appropriate treatment. Otherwise, in accordance with standards of care, a follow up visit in one year is suggested.
iPredict is indicated for use by healthcare providers in clinics, hospitals or other healthcare facilities to automatically detect DR, AMD and glaucoma suspect.
“This technology could be particularly useful in identifying someone who has slipped across the boundary to progress into severity,” Dr. Theodore Smith (Professor in Ophthalmology and Neuroscience at Icahn School of Medicine at Mount Sinai, New York) said.
“This is a major milestone for iHealthScreen. iPredict™ eye disease diagnostic tools will help prevent blindness for millions of people and save insurers countless millions of dollars in avoidable healthcare cost,” said Dr. Alauddin Bhuiyan, the founder and CEO of the company.